---
title: "Heartflow to Report Second Quarter 2026 Financial Results on August 13, 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293662324.md"
description: "California-based Heartflow, a pioneer in AI solutions for coronary artery disease, is set to unveil its financial performance for Q2 2026 post-market closing on August 13, 2026. Traded as HTFL on Nasdaq, the company will conduct a conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to delve into the financial outcomes. The announcement signifies a crucial juncture for investors and industry enthusiasts keen on Heartflow's status and trajectory in the realm of CAD technology."
datetime: "2026-07-23T20:02:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293662324.md)
  - [en](https://longbridge.com/en/news/293662324.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293662324.md)
---

# Heartflow to Report Second Quarter 2026 Financial Results on August 13, 2026

California-based Heartflow, a pioneer in AI solutions for coronary artery disease, is set to unveil its financial performance for Q2 2026 post-market closing on August 13, 2026. Traded as HTFL on Nasdaq, the company will conduct a conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to delve into the financial outcomes. The announcement signifies a crucial juncture for investors and industry enthusiasts keen on Heartflow's status and trajectory in the realm of CAD technology.

### Related Stocks

- [HTFL.US](https://longbridge.com/en/quote/HTFL.US.md)

## Related News & Research

- [Heartflow says new press release is available on SCCT 2026 plaque analysis data](https://longbridge.com/en/news/292195506.md)
- [Sam Altman said AI hasn't led to 4-hour workweeks because people are competitive](https://longbridge.com/en/news/293883472.md)
- [Humacyte says FDA accepts IND for first-in-human CTEV CABG study](https://longbridge.com/en/news/293928671.md)
- [APARINDS: Q1 FY2026-27 delivered robust growth and marked key international expansion moves](https://longbridge.com/en/news/293715931.md)
- [OSK: Q2 2026 sales rose 6.7% but margins declined; 2026 EPS guidance was revised lower](https://longbridge.com/en/news/294100394.md)